Open-Label Study of Latuda for the Treatment of Mania in Children and Adolescents 6-17 Years Old

Summary

This study is an 8-week open-label trial testing Lurasidone (Latuda®) as a treatment for mania in children and adolescents with Bipolar I, Bipolar II, and Bipolar Spectrum disorders. We hypothesize that Lurasidone will be safe, tolerable, and effective in improving the core symptoms of bipolar disorders in children and adolescents ages 6-17.

Timeline

Start

2017-01

Primary completion

2018-07

Completion

2018-07

Drugs

Indications